Jul. 3 at 12:19 AM
$VKTX from today’s apge release of Abbv negotiations
It is clear that Abbv felt comfortable dissection trials data in this immunology sector and as should be called “ bolt on “ deal.
From below Abbv was clearly looking at other opportunities at the same time .. likely still concerned about making Pfizer and Roche errors with no full data
“On June 8, 2026, a representative of AbbVie called Dr. Henderson and communicated that AbbVie would be submitting a written, non-binding proposal to acquire Apogee for an aggregate equity value of
$10 billion. The
representative of AbbVie conveyed that AbbVie would only be interested in transacting with Apogee if a transaction could be agreed quickly given, among other things, (i) the significant time AbbVie had invested in Apogee, beginning in 2023, (ii) competing demands for other opportunities and (iii) AbbVie’s desire to acquire Apogee with sufficient time to impact the long term development of Apogee’s products
